Disease · MONDO_0006920
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention (FIT2 Program) vs Usual Care: Number of Participants With New-onset Type 2 Diabetes Mellitus (DM) | 83 of 279 | 134 of 310 | 589 | NCT01926041 | Trial comparisons |
| Intervention (FIT2 Program) vs Usual Care: Number of Participants With Regression to Normoglycemia | 43 of 279 | 25 of 310 | 589 | NCT01926041 | Trial comparisons |
| Intervention (FIT2 Program) vs Usual Care: deaths from any cause | 0 of 279 | 0 of 310 | 589 | NCT01926041 | Trial comparisons |
| Intervention (FIT2 Program) vs Usual Care: serious adverse events | 0 of 279 | 0 of 310 | 589 | NCT01926041 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: deaths from any cause | 2 of 138 | 0 of 69 | 207 | NCT05040971 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: serious adverse events | 12 of 138 | 6 of 69 | 207 | NCT05040971 | Trial comparisons |
| Metformin/Dapagliflozin vs Metformin: deaths from any cause | 0 of 54 | 0 of 55 | 109 | NCT03968224 | Trial comparisons |
| Metformin/Dapagliflozin vs Metformin: serious adverse events | 0 of 54 | 0 of 55 | 109 | NCT03968224 | Trial comparisons |
| Metformin Alone vs Glargine Followed by Metformin: deaths from any cause | 0 of 47 | 0 of 44 | 91 | NCT01779375 | Trial comparisons |
| Metformin Alone vs Glargine Followed by Metformin: serious adverse events | 5 of 47 | 2 of 44 | 91 | NCT01779375 | Trial comparisons |
| Metformin vs Gastric Banding: deaths from any cause | 0 of 39 | 0 of 38 | 77 | NCT01763346 | Trial comparisons |
| Metformin vs Gastric Banding: serious adverse events | 2 of 39 | 4 of 38 | 77 | NCT01763346 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) | 10 of 20 | 18 of 25 | 45 | NCT02330549 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 0 of 20 | 0 of 25 | 45 | NCT02330549 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: deaths from any cause | 0 of 20 | 0 of 25 | 45 | NCT02330549 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: Number of Participants With Clinically Relevant Changes From Baseline in Vital Signs | 0 of 20 | 0 of 25 | 45 | NCT02330549 | Trial comparisons |
| Cenicriviroc 150 mg vs Placebo: serious adverse events | 0 of 20 | 1 of 25 | 45 | NCT02330549 | Trial comparisons |
| Acipimox vs Placebo: serious adverse events | 0 of 20 | 0 of 19 | 39 | NCT01488409 | Trial comparisons |
| Standard Care Plus Metformin vs Standard Care Plus Placebo: serious adverse events | 0 of 20 | 0 of 10 | 30 | NCT02179788 | Trial comparisons |
| Betaine vs Placebo: deaths from any cause | 0 of 14 | 0 of 13 | 27 | NCT01950039 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006920/comparisons